Erdafitinib Continues to Show Efficacy in Urothelial Carcinoma
The pan-FGFR tyrosine kinase inhibitor erdafitinib (Balversa) was active and safe in patients with locally advanced or metastatic urothelial carcinoma, according to long-term follow-up of a phase II study. At a median follow-up of 24 months, the investigator-assessed objective response rate (ORR) was 40% among 101 patients with prespecified FGFR alterations treated with erdafitinib, reported […]
Zanubrutinib Tops Ibrutinib in Relapsed or Refractory CLL
Treatment with the second-generation Bruton tyrosine kinase (BTK) inhibitor led to better oncologic outcomes compared with ibrutinib (Imbruvica) for patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), according to an interim analysis of the phase III ALPINE study. Over a median follow-up of 15 months, the overall response rate — the primary […]
Brepocitinib Shows Promise in Phase II Trial for PsA
The oral tyrosine kinase 2/Janus kinase 1 inhibitor brepocitinib showed efficacy for psoriatic arthritis (PsA) in a phase IIb trial. At week 16, a 20% improvement on the criteria of the American College of Rheumatology (ACR20) was observed in 66.7% of patients receiving 30 mg brepocitinib daily as did 74.6% of those given 60 mg […]